Menu

Flu Vaccine-Narcolepsy Link Explained?

A new study sheds light on why those who received GlaxoSmithKline’s flu vaccine were at an increased risk of developing the sleep disorder.

Dec 20, 2013
Jef Akst

WIKIMEDIA, PEDRO SIMOESEditor’s note (August 1, 2014): This paper was retracted after the authors failed to reproduce the results.

People suffering from narcolepsy may be victims of their own immune system, according to a study published this week (December 18) in Science Translational Medicine. Specifically, researchers have found evidence to suggest that the sleep disorder might result from an immune reaction against the wakefulness-regulating hormone hypocretin—possibly one triggered GlaxoSmithKline’s Pandemrix flu vaccine that has been linked to an increased risk of developing narcolepsy, or even a case of the flu itself.

The work reveals “the fingerprints of an immune attack,” neuroimmunologist Lawrence Steinman of Stanford University in Palo Alto, California, who was not involved in the research, told ScienceNOW.

The results are “exactly what we’ve been waiting for,” added vaccine expert Hanna Nohynek of the National Institute for Health and Welfare in Helsinki, who helped identify the link between Pandemrix and narcolepsy.

In 2009, narcolepsy researcher Emmanuel Mignot of Stanford University and colleagues, funded in part by a GSK grant, discovered a curious link between the sleep disorder and immunity: nearly all narcolepsy patients have a particular type of human leukocyte antigen (HLA), molecules that present antigens to T cells to help the immune system distinguish self from non-self. Working in an immune cell line with the narcolepsy-associated HLA, Mignot and his colleagues tested the effects of hypocretin on T cells from either from one of four narcolepsy patients or from their identical twins that didn’t suffer from the disorder. For each set of twins, the researchers found that the T cells from the affected individual reacted to pieces of hypocretin that were displayed by the HLAs; T cells from the unaffected twin did not react.

The researchers also tested the T cells of 10 Irish children who had developed the sleep disorder following the administration of the Pandemrix vaccine, along with those from healthy siblings who were also vaccinated and carried the same HLA type. Once again, only the T cells taken from the narcolepsy patients reacted to the hypocretin epitopes.

Mignot’s team also tested the effects of the H1N1 virus hemagglutinin protein, which resembles hypocretin epitopes, and found that fragments of the viral protein also elicited an immune reaction. The findings suggest that narcolepsy could result from the immune system reacting to native molecules as a result of their similar structure to pathogenic proteins.

“[This] is the first mechanistic explanation of the disease,” vaccine expert Steven Black of Cincinnati Children’s Hospital Medical Center in Ohio told ScienceNOW. Of course, he added, “there’s plenty of work to do” to fully understand what leads to the onset of narcolepsy.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing